Using diabetes medications after bariatric surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of continuing standard diabetes medications in patients who have undergone bariatric surgery. Traditionally, these medications are halted immediately after surgery, but this study aims to determine if ongoing use can enhance long-term diabetes control. By monitoring patients post-surgery, researchers will assess the safety and effectiveness of this approach in preventing relapse of diabetes symptoms. The study targets individuals with obesity and type 2 diabetes who meet specific eligibility criteria for bariatric surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* eligible for bariatric surgery according to NICE guidelines (GC 189)
* Type 2 diabetes mellitus
* BMI \>30kg/m2

Exclusion Criteria:

* Recent hospitalisation in the past 30 days
* Recurrent hypoglycaemic episodes
* Recurrent hypotensive episodes
* Contraindications to bariatric surgery
* Previous bariatric surgery
* Current pregnancy
* Breastfeeding

Where it's running

• University College Dublin
  Dublin, Ireland Recruiting

Study contacts

• Study coordinator: Alexander Miras, MRCP
• Email: a.miras@nhs.net
• Phone: : +44 (0)20 8383 3242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients

  This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.

  Recruiting Zhangzhou Municipal Hospital · Zhangzhou, Fujian · NCT07836088

• GUB-UCN2 in healthy, obese, and T2D adults: a first-in-human safety and pharmacology study

  This study tests GUB-UCN2 to see if it is safe and tolerable and how it behaves in the body in healthy adults, people with obesity, and people with obesity with or without type 2 diabetes.

  Recruiting Phase 1/2 Gubra A/S · Neuss · NCT07702890

• Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes

  This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.

  Recruiting Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 302 other locations · NCT07564414

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.